SCHEMBL4065348

SCHEMBL4065348

CC(C)Oc1cc(Nc2nc(N[C@@H](CO)c3ccc(F)cc3)nc(Cl)c2Cl)[nH]n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 16/20 0.72
JAK2 O60674 5/20 0.51
JAK3 P52333 4/20 0.51
AURKA O14965 2/20 0.51
NTRK3 Q16288 2/20 0.51
NTRK2 Q16620 2/20 0.51
KCNH2 Q12809 2/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
RET P07949 1/20 0.51
IGF1R P08069 1/20 0.51
FGFR1 P11362 1/20 0.51
FLT1 P17948 1/20 0.51
LTK P29376 1/20 0.51
KDR P35968 1/20 0.51
FLT3 P36888 1/20 0.51
CSNK1A1 P48729 1/20 0.51
CLK2 P49760 1/20 0.51
CDK7 P50613 1/20 0.51
CDK9 P50750 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077921 0.89 NTRK1 (0.77) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL4070199 0.88 NTRK1 (0.75) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL23217067 0.86 NTRK1 (0.80) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL29794572 0.86 NTRK1 (0.80) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL3340493 0.86 NTRK1 (0.80) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL4072619 0.81 NTRK1 (0.80) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL3343540 0.80 NTRK1 (0.54) NTRK1CDK9
SCHEMBL4068857 0.79 NTRK1 (0.78) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL4065930 0.76 NTRK1 (0.86) NTRK1JAK2JAK3AURKANTRK3
SCHEMBL4068254 0.76 NTRK1 (0.64) NTRK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1686999-B1 PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2009-07-01 EP disclosed
US-20090005396-A1 Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain ASTRAZENECA AB (SE) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005396-A1 Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain P2RX3, DPYD, TYMP NTRK1 3656/4885JAK2 1971/4885JAK3 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.